Andrea Sboner

Andrea Sboner

Auto-generated profile, based on publicly available information

Andrea Sboner

Englander Institute for Precision Medicine, Weill Cornell Medicine, New York, NY 10021, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in Cell
Verified
Journal Article
Closed access
SBSylvan C. Baca
Sylvan C. Baca
DPDavide Prandi
Davide Prandi
MLMichael S. Lawrence
Michael S. Lawrence
JMJuan Miguel Mosquera
Juan Miguel Mosquera
ARAlessandro Romanel
Alessandro Romanel
LGLevi A. Garraway
Levi A. Garraway

24 December 2010 in Science
Verified
Journal Article
Closed access
PDF file
MGMark B. Gerstein
Mark B. Gerstein
ZLZhi John Lu
Zhi John Lu
ENEric L. Van Nostrand
Eric L. Van Nostrand
CCChao Cheng
Chao Cheng
BABradley I. Arshinoff
Bradley I. Arshinoff
RWRobert H. Waterston
Robert H. Waterston
From Genome to Regulatory Networks: For biologists, having a genome in hand is only the beginning—much more investigation is still needed to characterize how the genome is used to help to produce a functional organism (see the Perspective by Blaxter ). In this vein, Gerstein et al. (p. 1775 ) summarize for the Caenorhabditis elegans genome, and The modENCODE Consortium (p. 1787 ) summarize for the Drosophila melanogaster genome, full transcriptome analyses over developmental stages, genome-wide identification of transcription factor binding sites, and high-resolution maps of chromatin organization. Both studies identified regions of the nematode and fly genomes that show highly occupied targets (or HOT) regions where DNA was bound by more than 15 of the transcription factors analyzed and the expression of related genes were characterized. Overall, the studies provide insights into the organization, structure, and function of the two genomes and provide basic information needed to guide and correlate both focused and genome-wide studies.

9 February 2011 in Nature
Verified
Journal Article
Open access
PDF file
MBMichael F. Berger
Michael F. Berger
MLMichael S. Lawrence
Michael S. Lawrence
FDFrancesca Demichelis
Francesca Demichelis
Yotam DrierYotam Drier
Yotam Drier
KCKristian Cibulskis
Kristian Cibulskis
LGLevi A. Garraway
Levi A. Garraway
Prostate cancer is the second most common cause of male cancer deaths in the United States. However, the full range of prostate cancer genomic alterations is incompletely characterized. Here we present the complete sequence of seven primary human prostate cancers and their paired normal counterparts. Several tumours contained complex chains of balanced (that is, ‘copy-neutral’) rearrangements that occurred within or adjacent to known cancer genes. Rearrangement breakpoints were enriched near open chromatin, androgen receptor and ERG DNA binding sites in the setting of the ETS gene fusion TMPRSS2–ERG, but inversely correlated with these regions in tumours lacking ETS fusions. This observation suggests a link between chromatin or transcriptional regulation and the genesis of genomic aberrations. Three tumours contained rearrangements that disrupted CADM2, and four harboured events disrupting either PTEN (unbalanced events), a prostate tumour suppressor, or MAGI2 (balanced events), a PTEN interacting protein not previously implicated in prostate tumorigenesis. Thus, genomic rearrangements may arise from transcriptional or chromatin aberrancies and engage prostate tumorigenic mechanisms.

1 November 2011 in Cancer Discovery
Verified
Journal Article
Closed access
PDF file
HBHimisha Beltran
Himisha Beltran
DRDavid S. Rickman
David S. Rickman
KPKyung Park
Kyung Park
SCSung Suk Chae
Sung Suk Chae
ASAndrea Sboner
Andrea Sboner
MRMark A. Rubin
Mark A. Rubin
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that most commonly evolves from preexisting prostate adenocarcinoma (PCA). Using next-generation RNA sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, and 5 benign prostate tissue (BEN) samples and validated findings in tumors from a large cohort of patients (37 with NEPC, 169 with PCA, and 22 with BEN) using immunohistochemistry and FISH. We discovered significant overexpression and gene amplification of AURKA and MYCN in 40% of NEPC and 5% of PCA tumors, respectively, and evidence that they cooperate to induce a neuroendocrine phenotype in prostate cells. There was dramatic and enhanced sensitivity of NEPC (and MYCN overexpressing PCA) to Aurora kinase inhibitor therapy both in vitro and in vivo, with complete suppression of neuroendocrine marker expression following treatment. We propose that alterations in Aurora kinase A and N-myc are involved in the development of NEPC and that future clinical trials will help determine the efficacy of Aurora kinase inhibitor therapy. Significance: We report on the largest in-depth molecular analysis of NEPC and provide new insight into molecular events involved in the progression of prostate cancer. Cancer Discovery; 1(6); 487–95. ©2011 AACR. Read the Commentary on this article by Aparicio et al., p. 466 This article is highlighted in the In This Issue feature, p. 457

5 June 2013 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
CACristina R. Antonescu
Cristina R. Antonescu
FLFrancois Le Loarer
Francois Le Loarer
JMJuan‐Miguel Mosquera
Juan‐Miguel Mosquera
ASAndrea Sboner
Andrea Sboner
LZLei Zhang
Lei Zhang
CFChristopher D. M. Fletcher
Christopher D. M. Fletcher

4 October 2013 in Science
Verified
Journal Article
Closed access
PDF file
EKEkta Khurana
Ekta Khurana
YFYao Fu
Yao Fu
VCVincenza Colonna
Vincenza Colonna
XMXinmeng Jasmine Mu
Xinmeng Jasmine Mu
HKHyun Min Kang
Hyun Min Kang
MGMark Gerstein
Mark Gerstein
Identifying Important Identifiers: Each of us has millions of sequence variations in our genomes. Signatures of purifying or negative selection should help identify which of those variations is functionally important. Khurana et al. ( 1235587 ) used sequence polymorphisms from 1092 humans across 14 populations to identify patterns of selection, especially in noncoding regulatory regions. Noncoding regions under very strong negative selection included binding sites of some chromatin and general transcription factors (TFs) and core motifs of some important TF families. Positive selection in TF binding sites tended to occur in network hub promoters. Many recurrent somatic cancer variants occurred in noncoding regulatory regions and thus might indicate mutations that drive cancer.